Medical Device Coating Using PDEA to Mitigate Biofilm Growth

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing medical device coatings are inadequate in preventing the formation and growth of biofilms, which are resistant to antimicrobials and contribute to antibiotic resistance, posing a significant challenge in healthcare due to increased morbidity and mortality from chronic infections.

Innovation Solution

A coating comprising a polymer with covalently or ionically bonded 2-(pyridyldithio)ethylamine (PDEA) or a closely related compound, present in low amounts, effectively prevents biofilm formation by adhering to medical devices without bactericidal or bacteriostatic effects, utilizing free carboxyl groups and amino groups for bonding.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If traditional antimicrobial coatings are used, then bacterial growth is inhibited, but biofilm formation still occurs and antibiotic resistance increases

Engineering Contradiction:

Improvebacterial growth inhibitionVSAvoidbiofilm prevention effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the chemical parameter of the coating by using PDEA (2-(pyridyldithio)ethylamine) instead of traditional antimicrobials. This parameter change allows the coating to prevent biofilm formation without killing bacteria, thereby maintaining bacterial growth inhibition while improving biofilm prevention effectiveness and reducing antibiotic resistance development.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful effect of traditional antimicrobials (killing bacteria) into a beneficial approach by using PDEA that prevents biofilm formation without bactericidal activity. This transforms the mechanism from direct bacterial elimination to biofilm prevention, which is the actual harmful factor in chronic infections.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If high concentrations of antimicrobials are used in coatings, then biofilm formation is reduced, but cytotoxicity and chemical load increase

Engineering Contradiction:

Improveantibiofilm efficacyVSAvoidcytotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the concentration parameter by using low amounts of PDEA (0.001-1 wt%) instead of high concentrations of traditional antimicrobials. This parameter change maintains antibiofilm efficacy while significantly reducing cytotoxicity and chemical load, as PDEA exerts its effect through biofilm prevention mechanisms rather than bactericidal activity.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses a small amount of PDEA that is covalently bonded to the polymer coating, acting as a durable but low-concentration antimicrobial agent. This approach replaces the need for high concentrations of traditional antimicrobials, reducing overall chemical load and cytotoxicity while maintaining effectiveness.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Strength

If conventional coatings are applied to medical devices, then surface adherence is improved, but biofilm still forms and penetrates the coating

Engineering Contradiction:

Improvesurface adherenceVSAvoidbiofilm penetration resistance

Core Design Contradiction:

StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical composition parameter of the coating by incorporating PDEA covalently bonded to the polymer matrix. This parameter change enhances surface adherence while simultaneously preventing biofilm formation and penetration, as PDEA interferes with biofilm matrix production and bacterial adhesion at the coating surface.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite coating material combining polymer matrix with covalently bonded PDEA. This composite structure provides both the mechanical integrity of the polymer and the antibiofilm properties of PDEA, preventing biofilm penetration while maintaining surface adherence.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The coating significantly reduces biofilm formation on medical devices, maintaining device functionality and safety, simplifying regulatory approval by minimizing cytotoxicity and chemical use, while maintaining antibiofilm efficacy over several days.

Implementation Method 1

2-(pyridyldithio)ethylamine (PDEA) or a closely related compound covalently bonded to a polymer

Methodology Applied

Scientific EffectCovalent bonding: Chemical Bonding

Implementation Method 2

amino groups for bonding... covalently or ionically bonded

Methodology Applied

Scientific EffectIonic bonding: Ion Repulsion/Attraction

Implementation Method 3

adhering to medical devices without bactericidal or bacteriostatic effects

Methodology Applied

Scientific EffectAdhesion: Adhesive

Data Source

PatentUS12514962B2Medical device comprising a coating for mitigation of formation and/or growth of biofilm

Publication Date: 2026.01.06 CYTACOAT AB

AI summary

The invention concerns a medical device comprising a coating, said coating comprising: polymer Z bonded to the medical device and moieties of Formula (A), wherein X is an amino group which is covalently bonded to Z or which can ionically bind to free carboxyl groups, wherein the moieties according to Formula A are present in the coating at an amount of 05-30 nmol/cm2; and wherein polymer Z comprises free carboxyl groups in an amount of 1-30 μmol/cm2.